GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.
Heng-Chih PanJui-Yi ChenHsing-Yu ChenFang-Yu YehChiao-Yin SunThomas Tao-Min HuangVin-Cent WuPublished in: Nature communications (2024)
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.
Keyphrases
- cardiovascular events
- cardiovascular disease
- coronary artery disease
- type diabetes
- wild type
- end stage renal disease
- glycemic control
- acute kidney injury
- human health
- newly diagnosed
- ejection fraction
- intensive care unit
- chronic kidney disease
- clinical trial
- insulin resistance
- prognostic factors
- risk assessment
- electronic health record
- adipose tissue
- climate change
- skeletal muscle
- respiratory failure
- machine learning
- big data
- peritoneal dialysis
- drug induced
- case control
- extracorporeal membrane oxygenation
- double blind
- combination therapy
- patient reported